Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21567217 | 0.87 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3774097 | 0.85 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498678 | 0.82 | ADORA2A (0.48) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498669 | 0.81 | ADORA2A (0.50) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7070989 | 0.78 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20402660 | 0.77 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498498 | 0.76 | PRKCI (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL29998653 | 0.76 | PRKCI (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL11319172 | 0.75 | PDE7A (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL4208839 | 0.75 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| CN-118401243-A | Methods of treating neurodegenerative diseases | PTC医疗公司 | 2024-07-26 | — | — | CN | claimed |
| EP-4398988-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-4288059-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023039370-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | claimed |
| EP-4072677-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115209955-A | Compounds for the treatment of familial autonomic nerve dysfunction | PTC医疗公司 | 2022-10-18 | — | — | CN | claimed |
| WO-2022169868-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021118929-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022169868-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SNRPB2, SYNCRIP, HNRNPUL2 | PDE4A 111/4885PDE4B 88/4885PDE4C 161/4885 |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | PDE4A 176/4885PDE4B 249/4885PDE4C 190/4885 |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | PDE4A 2213/4885PDE4B 1985/4885PDE4C 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.